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Abstract
The present study evaluated the effect of various dosages of soybean isoflavone extract on body weight changes, glucose tolerance and liver
function in streptozotocin-induced diabetic rats. One group of normal rats (normal control) was fed an AIN-76-based experimental diet and four
groups of diabetic rats were fed the same diet supplemented with four different levels of soybean isoflavone extract for seven weeks. The daily 
dosages of pure isoflavone for four diabetic groups were set to be 0 mg (diabetic control), 0.5 mg (ISO-I), 3.0 mg (ISO-Ⅱ) and 30.0 mg (ISO-Ⅲ)
per kilogram of body weight, respectively. The daily consumption of isoflavone at the level of 3.0mg per kilogram of body weight resulted in
the suppression of body weight loss and increased the survival rate of diabetic animals one and half times compared to that of the diabetic control
group. Blood glucose levels in a fasting state and after the oral administration of glucose were significantly lower in the ISO-II group during the
oral glucose tolerance test. The ISO-II group showed a tendency to elongate the gastrointestinal transit time. The activity of serum aminotransferases,
indicator of liver function, was not negatively affected by any intake level of isoflavone. The present study demonstrated that the soybean isoflavone
extract may be beneficial to diabetic animals by improving their glucose tolerance and suppressing weight loss without incurring hepatotoxicity
at the daily dosage of 3.0 mg per kg of body weight. 
Key Words: Soybean isoflavone extract, streptozotocin, diabetic rat, glucose tolerance, survival rate
Introduction4)
In recent years, there has been an increased interest with regard 
to dietary phytoestrogens, especially isoflavones, among the 
public and in the medical community because of their potential 
role in promoting health (Ren et al., 2001; Setchell & Cassidy, 
1999; Tham et al., 1998). The most abundant food sources of 
isoflavones are soybean and soybean products (Wang & Murphy, 
1994). Soybean isoflavone has been examined for its beneficial 
effects on clinical and metabolic variables in animals and 
humans. Soybean isoflavone have been reported to act as a 
selective estrogen receptor modulator (Setchell, 2001), possess 
potential for antioxidant activity (Lajolo et al., 2005; Ruiz-Larrea 
et al., 1997; Wei et al., 1995), and lower blood cholesterol levels 
(Jenkins et al., 2002; Hermansen et al., 2001; Anderson et al., 
1998). Substantial data from epidemiological surveys and clinical 
intervention trials involving animals and humans strongly support 
the beneficial effect of isoflavone-rich soy protein in preventing 
various chronic diseases including, cardiovascular disease (Goodman- 
Gruen & Kritz-Silverstein, 2001; Teede, 2001), cancer (Zhang 
et al., 2004; Hussain et al., 2003; Constantinou et al., 2001; Chen 
& Anderson, 2001), osteoporosis (Alekel et al., 2000; Arjmandi 
et al., 1996), and menopausal symptoms (Somekawa et al., 2001; 
Upmalis et al., 2000; Alekel et al., 2000; Washburn et al., 1999; 
Baird  et al., 1995). 
Evidence is also emerging that soy may have a beneficial role 
on obesity and diabetes in animals and humans (Lee, 2006; 
Bartke  et al., 2004; Hsu et al., 2003; Bhathena & Velasquez, 
2002; Vedavanam et al., 1999). Several studies have evaluated 
the effect of proteins from different sources in obese humans 
and found that soy protein possesses significant antiobesity 
activity with a reduction of serum cholesterol and triacylglycerol 
(Bosello et al., 1998; Yamashita et al., 1998). Studies conducted 
with obese animals reported that the consumption of soy products 
decreased body weight and plasma glucose level (Aoyama et al., 
2000; Saito, 1991). It has been reported that soy protein, with 
its associated isoflavones and fiber, reduced lipid levels and 
cardiovascular risk markers in Type 2 diabetic subjects, as 
compared with a casein diet with cellulose but it did not have 
any effect on glucose metabolism (Hermansen et al, 2001). 
However, it was demonstrated that defatted soy flour, when 
added to whole-durum meal, decreased hyperglycemia as well 
as hyperlipidemia in Alloxan diabetic rats (Taha & Wasif, 1996). 
Vedavanam et al (1999) suggested that a soybean phytochemical 
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Table 1. The composition of the experimental diets
Ingredients
Experimental groups
Control ISO-Ⅰ ISO-Ⅱ ISO-Ⅲ
g/100g diet
  Cornstarch 15.00 15.00 15.00 15.00
  Sucrose 50.00 50.00 50.00 50.00
  Casein 20.00 20.00 20.00 20.00
  Corn oil  5.00  5.00  5.00  5.00
  Cellulose  5.00  5.00  5.00  5.00
AIN-76 Vitamin mix
1) 
AIN-76 Mineral mix
2)
Cholinechloride
DL-methionine
 1.00
 3.50
 0.20
 0.30
 1.00
 3.50
 0.20
 0.30
 1.00
 3.50
 0.20
 0.30
 1.00
 3.50
 0.20
 0.30
mg/100g diet
Isovone 40
3)
  total pure isoflavone
 0.00
 0.00 
 1.03
 0.42
 6.20
 2.53
62.00
25.35
1) AIN-76 vitamin mix (g/kg mix): thiamin․HCl 0.6, riboflavin 0.6, pyridoxine HCl 0.7, 
nicotinic  acid  3,  D-calcium  pantothenate  1.6,  folic  acid  0.2,  cyanocobalamin 
0.001,  retinyl  palmitate  0.8  (500,000  IU/g),  DL-α-tocopherol  acetate  20  (2501 
IU/g),  cholecalciferol  0.0025,  menaquinone  0.005,  and  sucrose  to  make  1kg 
2) AIN-76 mineral mix (g/kg mix) : calcium phosphate dibasic 500, sodium chloride 
74, potassium citrate monohydrate 220, potassium sulfate 52, magnesiumoxide 
24,  manganous  carbohydrate  3.5,  ferric  citrate  6,  zinc  carbonate  1.6,  cupric 
carbonate 0.3, potassium iodate 0.01, sodium selenite 0.01, chromium potassium 
sulfate  0.55,  and  sucrose  to  make  1kg. 
3) Isovone 40 (Product No. HF-2002-038, Bioland Inc. Seoul, Korea) contains 40.9% 
of th e to tal p u re isoflavo ne w hich  co nsists o f 3 6.9 %  total ag lycone type (22% 
daidzein,  11.7%  glycitein,  6.39%  genistein)  and  4%  of  a  total  glycoside  type. 
extract displayed a range of properties which may be beneficial 
for diabetes, namely as an estrogenic agent, as an inhibitor of 
intestinal glucose-uptake and a preventive agent for glucose- 
induced lipid peroxidation. Hence, soybean isoflavone is expec-
ted to improve the overall metabolism in diabetes that is asso-
ciated with chronic hyperglycemia and disturbances of carbo-
hydrate and lipid metabolism. 
The lipid-lowering effect of soy protein has been relatively 
well documented, however, studies on the effects of soy on glu-
cose metabolism are lacking and the effect of soy protein and 
isoflavones on glucose metabolism is still unclear. Recently, the 
effect of soy isoflavone on blood glucose in streptozotocin- 
induced diabetic rats have been reported (Lee, 2006; Hsu et al., 
2003) but the results were inconsistent. Hsu et al. (2003) 
supplemented a diet with isoflavone (240~1920mg/100g diet) for 
24 days and found no favorable effect on plasma glucose. Lee 
(2006) tested genistein (600mg/kg diet) and soy protein (200g/ 
kg diet)-supplemented diets for 3 weeks and reported a beneficial 
effect in correcting hyperglycemia in diabetic animals. In both 
studies, the dosages of isoflavones were tremendously high and 
the feeding periods were relatively short. Therefore, isoflavones 
need to be tested at more realistic dosages for a longer period 
of time, since the safety of isoflavones has not been established 
yet. 
The present study examined the effect of the supplementation 
of soybean isoflavone extract at various dose levels for seven 
weeks on glucose tolerance, body weight changes and diabetic 
symptoms in streptozotocin-induced diabetic rats. The second 
purpose of this study was to determine the dosage of dietary 
isoflavone, which may exhibit beneficial effect on diabetic animal 
without hepatic toxicity. 
Materials and Methods 
Animals and diet 
Eighty weanling male Sprague-Dawley rats (Biogenomics Co., 
Korea) were raised on a chow diet (Jeil Animal Feed Co., Korea) 
until they weighed over 200 g and then they were fed an AIN 
76-based diet (American Institute of Nutrition, 1977) for 1 week 
prior to the experiment. Ten rats were assigned to the normal 
control group and seventy were experimentally induced to a 
diabetic condition. Diabetic rats were divided into four groups 
according to body weight and blood glucose levels in order to 
have similar weights and levels in each of the groups. The normal 
control group (n=10) was fed an AIN-76-based experimental diet 
and four groups of diabetic rats were fed the same diet supple-
mented with four different levels of soybean isoflavone extract, 
0 mg (diabetic control, n=16), 0.42 mg (ISO-I, n=18), 2.53mg 
(ISO-II, n=18), and 25.35mg (ISO-III, n=18) isoflavone per 100g 
diet, respectively. When assuming that the average daily feed 
intake of a mature rat is approximately 30 g, the daily dosages 
of isoflavone are estimated to be 0 mg (normal and diabetic 
control), 0.5 mg (ISO-I), 3.0 mg (ISO-Ⅱ), and 30.0 mg (ISO-Ⅲ) 
per kilogram of body weight, respectively. The daily dose of 
isoflavone for the ISO-I group (0.5 mg/kg body weight) was set 
to be approximately equivalent to the average daily isoflavone 
intake of Korean adult women, (Lee et al., 2000) and the dose 
for the ISO-II group (3.0 mg/kg body weight) was 6 times that 
of ISO-I group which was approximately equivalent to the 
maximum daily isoflavone intake of Korean adult women (Lee 
et al., 2000). The dose for the ISO-III group (30 mg/kg body 
weight) was 60 times that of the ISO-I group and this level was 
set in order to evaluate any possible additive or adverse effects 
of the high dose of isoflavone. The source of isoflavone was 
ISOVONE 40 (Bioland, Seoul, Korea) which was a soybean 
isoflavone extract that contained 40.9% of total pure isoflavone. 
All diets contained an identical concentration of energy and 
nutrients (Table 1). The animals were fed experimental diets and 
filtered tap water ad libitum for seven weeks. 
The induction of diabetes and the evaluation of changes in body 
weight
Diabetes was induced by a single femur intramuscular injection 
of streptozotocin (STZ, Sigma Chemical, St Louis, MO, USA) 
at a dose of 50 mg/kg BW. STZ was dissolved immediately 
before use in a 0.1 M citrate buffer (pH 4.5). The same amount 
of citrate buffer (0.1 M, pH 4.5) was injected into the normal 
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Table 2. The effect of soybean isoflavone extract supplementation on the body
weight changes and survival rate of STZ-induced diabetic rats 
Groups
Initial body 
weight
(g) 
Final body 
weight
(g)
Body weight 
gain
(g / 7 weeks)
Survival 
rate
(%)
Normal control 
(10/10)
2)
260.00±3.03
NS 1) 522.50±14.45
A 262.50±11.67
A 100
Diabetic control 
(16/8)
259.38±2.83
ns 277.36±9.18
Ba 17.99±10.04
Ba  50
Diabetic ISO-Ⅰ 
(18/9)
257.44±7.33 280.89±13.26
Ba 23.45±8.72
Ba  50
Diabetic ISO-II 
(18/13)
256.92±6.23 314.46±10.07
Bb 57.53±12.07
Bb  72
Diabetic ISO-Ⅲ 
(18/12)
255.75±6.18 289.25±2.11
Ba 33.50±6.08
Bb  67
A b b r e v ia t i o n s :  I S O  :  i s o f l a v o n e ,  S T Z  :  s t r e p t o z o t o c i n 
1) Mean±S.E. 
2) Number  of  animals  (initial/final) 
Different  capital  superscripts  in  the  same  column  indicate  significant  differences
(p＜0.05)  among  5  groups  by  Duncan's  multiple  comparison  test. 
Different  small  superscripts  in  the  same  column  indicate  significant  differences
(p＜0.05)  among  4  diabetic  groups  by  Duncan's  multiple  comparison  test. 
NS  Not  significantly  different  among  the  5  groups  (p＜0.05) 
ns  Not  significantly  different  among  the  4  diabetic  groups  (p＜0.05) 
the tail vein of the rats in the fasting state. The rats were 
considered to be diabetic only if their fasting blood glucose levels 
exceeded 180 mg/dL. The maintenance of a diabetic state was 
confirmed by measuring the fasting blood glucose level at week 
5 of the experimental period. The weights of the animals were 
measured using an animal balance once a week during the seven 
week period. 
The Survival rates
The Survival rate was calculated as the ratio of the number 
of animals survived at the end of experimental period to the 
number of animals at the beginning of the experiment.
Measuring gastrointestinal (GI) transit time 
At the week 4 of the experiment, the animals were fed 
experimental diets, mixed with 0.5% Carmine red (Sigma Che-
mical, St Louis, MO. USA), which acts as a marker of GI transit. 
The excretion of the marker in the feces was checked every hour 
after feeding. The time interval between the initiation of feeding 
and the first detection of the marker in the feces was considered 
to be the GI transit time. 
Assessing diabetic symptoms 
During week 6 of the experimental period, each animal was 
held in a metabolic cage for 48 hours. Food intake, water intake 
and excreted urine volume were measured in order to assess the 
diabetic symptoms of the animals. Urine was collected in a 50 
mL centrifuge tube treated with a few drops of toluene as 
preservative. 
Oral glucose tolerance test (OGTT) 
During week 7 of the experiment, the animals were deprived 
of their diets for 12 hours and the fasting blood sugar levels 
were measured from the tail vein. Subsequently, the oral 
administration of a 50% glucose solution (0.1 g glucose/100 g 
BW), using an intubation tube, was followed, and the postpran-
dial blood sugar levels were measured from the tail vein at 30, 
60, 120 and 180 minutes after ingestion. The blood glucose levels 
were measured using a blood glucose measuring instrument 
(Accutrend GC, Boehringer Mannheim, Germany). 
Preparing blood and tissue samples 
After fasting for 12 hours, animals were anesthetized by an 
intraperitoneal injection of 0.2 mL of 1% Ketamin hydrochloride 
per 100 g body weight, and the abdomen was opened. Blood 
was drawn from the inferior vena cava by heparinized syringes, 
and plasma was obtained by centrifugation at 3,000 rpm for 20 
minutes, and stored frozen at -70℃ until analyses were perfor-
med. Liver, kidney, heart, and lung tissue samples were excised, 
and fat was removed. The samples were rinsed 3 times with a 
cold saline and blotted dry, weighed, and then frozen in liquid 
nitrogen. 
Measuring plasma activities of glutamic oxaloacetic transa-
minase (GOT) and glutamic pyruvic transaminase (GPT). 
The activity of GOT and GPT in the plasma samples was 
measured using an enzymatic analysis kit (Asan Pharmaceuticals, 
Hwasung, Korea), according to the Reitman-Frankel method 
(Reitman & Frankel, 1957). 
Statistical analysis
Data were presented as means and standard errors. Group 
means were compared by an Analysis of Variance using 
Duncan’s multiple range test and differences were considered 
to be statistically significant at a p value of less than 0.05. All 
statistical tests were performed using the SPSS program for 
Windows (SPSS, Chicago, IL, USA: Version 10.0) 
Results 
Body weight change and survival rates
There were no significant differences in the initial body weight 
among all of the groups, however, after seven weeks of the 
testing, the final body weights and the mean body weight gains 
were significantly lower (p<0.05) in all diabetic groups, as 
compared with the normal control group. Among the diabetic 
groups, the mean weight gains of the ISO-II and ISO-III groups 
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Table 3. The effect of soybean isoflavone extract supplementation on organ 
weights in STZ-induced diabetic rats 
Groups(n)
2) Liver Kidney Heart Lung 
(g/100g BW)
Normal control(10) 3.75 ±0.26
A 1) 0.62±0.03
A 0.30±0.01
A 0.41±0.03
NS
Diabetic control (8) 4.84±0.13
Ba 1.44±0.06
Bns 0.37±0.08
Bns 0.55±0.03
ns
Diabetic ISO-I  (9) 4.37±0.07
Bb 1.30±0.04
B 0.36±0.01
B 0.53±0.01
Diabetic ISO-Ⅱ(13) 4.40±0.19
Bb 1.22±0.05
B 0.35±0.01
B 0.47±0.02
Diabetic ISO-Ⅲ(12) 4.36±0.11
Bb 1.34±0.05
B 0.35±0.10
B 0.55±0.03
Abbreviations:  ISO:  soybean  isoflavone  extract,  STZ  :  streptozotocin 
1)Mean±S.E. 
2)Number  of  animals 
Different  capital  superscripts  in  the same  column indicate  significant differences
(p＜0.05)  among  5  groups  by  Duncan's  multiple  comparison  test. 
Different small superscripts in the same column indicate significant differences 
(p＜0.05)  among  4  diabetic  groups  by  Duncan's  multiple  comparison  test. 
NS  Not  significantly  different  among  the  5  groups  (p＜0.05) 
ns  Not  significantly  different  among  the  4  diabetic  groups  (p＜0.05) 
Table 4. The effect of soybean isoflavone extract supplementation on food and
water intake and urine excretion in STZ-induced diabetic rats at week 5 of the 
experimental diet feeding 
Groups(n)
2) Food intake Water intake Urine Volume
(g/100g BW/d) (mL/100g BW/d) (mL/100g BW/d)
Normal control (10)  5.29±0.33
A 1)   9 . 6 4 ± 2 . 7 2
A  9.43±0.16
A
Diabetic control (8) 12.46±0.55
Bns 113.46±6.36
Bns 78.39±5.97
Bns
Diabetic ISO-Ⅰ (9) 12.53±0.72
B 107.09±6.75
B 74.45±6.32
B
Diabetic ISO-Ⅱ (13) 11.36±0.74
B 104.96±10.65
B 69.16±7.19
B
Diabetic ISO-Ⅲ (12) 12.46±0.78
B 117.67±11.75
B 83.48±6.01
B
Abbreviations  :  ISO:  isoflavone,  STZ:  streptozotocin 
1)Mean±S.E. 
2)Number  of  animals 
Different  capital  superscripts  in  the  same  column  indicate  significant  difference
(p＜0.05)  among  5  groups  by  Duncan's  multiple  comparison  test. 
D i f f e r e n t  sm a ll s up e rscri p t s in  th e sa m e co lum n  ind ica te  sig nificant difference
(p＜0.05)  among  4  diabetic  groups  by  Duncan's  multiple  comparison  test. 
ns  Not  significantly  different  among  the  4  diabetic  groups  (p＜0.05)
Table 5. The effect of soybean isoflavone extract supplementation on 
gastrointestinal (GI) transit time in STZ-induced diabetic rats 
Group(n)
2) GI transit time (hr)
Normal control(10) 14.70±0.56
a 1)
Diabetic control(8) 10.75±0.65
b
Diabetic ISO-Ⅰ(9) 11.55±1.48
b
Diabetic ISO-Ⅱ(13) 12.69±0.10
ab
Diabetic ISO-Ⅲ(12) 11.58±1.24
b
Abbreviations  ;  ISO  :  isoflavone,  STZ  :  streptozotocin 
1)Mean±S.E. 
2)Number  of  animals 
Different superscripts in the same column indicate significant differences (p＜0.05) 
between  the  5  groups  by  Duncan's  multiple  comparison  test. 
Fig. 1. Blood glucose curves during OGTT in normal and diabetic rats. 
At week 7 of the experimental period, the rats were administered with a glucose 
solution (0.1 g/100g B.W.) and the plasma glucose was determined at 0, 30, 60, 
120,  180min  after  glucose  load.  Abbreviations:  ISO:  soybean  isoflavone  extract. 
Different  capital  letters  at  the  same  time  point  indicate  significant  differences
(p<0.05) among the five groups and different small letters at the same time point 
indicate significant differences (p<0.05) among the four diabetic groups by Duncan's 
multiple  comparison  test. 
control and ISO-Ⅰgroups.  The survival rates of the diabetic 
groups were lower than that of the normal control group. Among 
the diabetic groups, the ISO-II and ISO-III groups showed higher 
survival rate than that of the diabetic control or ISO-I groups 
(Table 2). 
Organ weights
The mean relative weights of the liver, kidney and heart of 
all diabetic groups were significantly higher (p<0.05) than those 
of the normal control group. All of the isoflavone-supplemented 
groups tended to have lower mean organ weights than those of 
the diabetic control group even though the differences were not 
statistically significant (Table 3). 
Diabetic symptoms
Feed and water consumption, and the volume of urine excretion 
for all diabetic groups were significantly (p<0.05) higher than 
those of the normal control group. Among the diabetic groups, 
the ISO-II group showed the lowest consumption of feed and 
water, and the least urine volume compared to other diabetic 
groups (Table 4). 
The gastrointestinal (GI) transit time
The mean GI transit time of the diabetic groups was signifi-
cantly (p<0.05) shorter than that of the normal control group. 
Among the diabetic groups, the mean GI transit time of the ISO-II 
group was longer than that of the other diabetic groups, but 
similar to that of the normal control group (Table 5). 
Glucose tolerance
In the oral glucose tolerance test, the diabetic groups had 
significantly higher levels of blood glucose (p<0.05) than the 
normal control group. Among the diabetic groups, the ISO-II 
group showed significantly lower (p<0.05) fasting and postp-
randial blood glucose levels at all time points compared with 
the other diabetic groups. With regard to the time-course change, 
blood glucose reached its highest level at 30 minutes after the 
administration of glucose regardless of the group type. The levels 
were decreased gradually and returned to their fasting levels at 
120 minutes for the ISO-I and ISO-II groups, and at 180 minutes 
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Table 6. The effect of soybean isoflavone extract supplementation on the 
activity of plasma transaminases in STZ-induced diabetic rats 
Groups(n)
2) GOT GPT
(karmen/mL)
Normal control(10) 98.32±4.51
NS 1) 35.99±2.92
A
Diabetic control(8) 96.65±5.28
ns 47.97±3.42
Ba
Diabetic ISO-Ⅰ(9) 94.23±4.77 43.18±2.46
Ba
Diabetic ISO-Ⅱ(13) 95.79±5.01 34.99±2.12
Ab
Diabetic ISO-Ⅲ(12) 93.13±6.91 33.50±2.68
Ab 
Abbreviations:  ISO:  isoflavone,    STZ:  streptozotocin,  GOT:  glutamic  oxaloacetic 
transaminase,  GPT:  glutamic  pyruvate  transaminase 
1)Mean±S.E. 
2)Number  of  animals 
Different capital superscripts in the same column indicate significant differences
(p＜0.05)  among  the  5  groups  by  Duncan's  multiple  comparison  test. 
Different small superscripts in the same column indicate significant differences
(p＜0.05)  among  the  4  diabetic  groups  by  Duncan's  multiple  comparison  test. 
NS  Not  significantly  different  among  the  5  groups  (p＜0.05) 
ns  Not  significantly  different  among  the  4  diabetic  groups  (p＜0.05) 
The activity of GOT and GPT in plasma
There were no significant differences regarding the plasma 
GOT activity in any of the groups, however, GPT activity was 
significantly lower (p<0.05) in the normal, ISO-I, ISO-II groups 
than in the diabetic control and ISO-I groups (Table 6). 
Discussion
The present study investigated the effect of diet that contained 
different levels of soy isoflavone extract with regard to changes 
in body weight and the survival rate of diabetic animals, as an 
indicator of overall health conditions. It has been observed that 
the supplementation of soybean isoflavone, at the intake levels 
of 3.0 and 30 mg per kilogram of body weight per day, resulted 
in the suppression of body weight loss and an increase in the 
survival rate of the diabetic animals compared to the diabetic 
control group. Even though animal model was different, Bartke 
et al. (2004) recently reported that a dietary isoflavone intake 
can prolong lifespan and enhance the capacity for glucose 
tolerance in normal mice. Hermansen et al. (2001) demonstrated 
that soybean and its isoflavones had a beneficial effect on 
carbohydrate and lipid metabolism in diabetic animals. Other 
studies (Ali et al., 2004; Bhatena & Velasquez, 2002) also 
provided evidence regarding a wide range of health benefits of 
soybean isoflavones in diabetes including favorable altering of 
insulin resistance, glycemic control, and serum lipid control. 
Based on these results, it appears that soybean isoflavones could 
improve the overall metabolism of diabetic animals, thus resul-
ting in suppressing weight loss and increasing the survival rates. 
However, the exact mechanisms by which isoflavones exhibited 
their beneficial effect on reducing death rate of diabetic animals 
remain unclear. 
After seven weeks of being fed a diet, all diabetic groups 
showed significantly higher organ weights (liver, kidney and 
heart), as compared to those of the normal control group. In 
particular, the average size of the kidney of the diabetic groups 
was more than twice that of the normal group, indicating that 
renal enlargement commonly occurs in diabetes. Among the 
diabetic groups, however, the isoflavone-supplemented groups 
showed significantly lower liver weight and relatively lower 
overall organ weight compared to the diabetic control group. 
Similar results were reported by Ali et al. (2004), in which 
isoflavone significantly decreased liver and kidney weights in 
both lean and obese SHR/N-cp rats which are a genetic animal 
model of obesity and type 2 diabetes. Even though the fat content 
in organs was not measured, we could guess that soybean 
isoflavones may reduce the accumulation of fat in the liver and 
kidney since the antilipogenic effect of isoflavones had been 
reported in previous studies (Naaz et al., 2003; Duncan et al., 
1999; Kawano-Takahashi, 1986). In diabetes, long-lasting hyper-
glycemia has been known to lead to chronic renal complications 
and finally, proteinuria and uremia (Humphrey & Ballard, 1990). 
There are several studies which have reported on the beneficiary 
effect of dietary soybean and soy protein with regard to imp-
roving kidney function in Type II diabetes with the nephropathy 
(Teixeira et al., 2004; Azadbakht et al, 2003) or retardation of 
the development and progression of chronic renal disease in 
human and animals (Anderson et al., 1999). The results of this 
study support the possibility that isoflavones in soybeans might 
be effective in preventing renal enlargement in diabetic animals. 
Although our data demonstrated that supplementing with 
isoflavone is favorable to body weight maintenance and surviving 
of diabetic animals, there was no significantly positive effect on 
the alleviating classical diabetic symptoms, the so called "3 polys 
(polydipsia, polyuria, polyphagia)". However, the ISO-II group 
showed the least consumption of water and feed and the least 
excretion of urine among the diabetic groups. Therefore, it is 
expected that, when the period of supplementation is longer, 
soybean isoflavones may reveal a more evident effect on less-
ening diabetic symptoms through improving the overall meta-
bolism in the diabetic animals.
The present study demonstrated that a certain level of soybean 
isoflavones supplement may improve glycemic control in diabetic 
rats. The intake level of isoflavones, which exerted a favorable 
effect on glucose tolerance, was 3.0 mg per kilogram of body 
weight (ISO-II group). With regard to glycemic control by soy 
isoflavones, there have been inconsistent reports. Hsu et al. 
(2003) examined the effect of diets that contained different levels 
of isoflavones on diabetic animals and reported that there were 
no differences in plasma glucose or insulin levels. Animals were 
fed with tremendously high levels of isoflavones (240, 480, 1920 
mg/100g diet) in that experiment, compared with this study (0.4, 
2.5, 25 mg/100g diet). When considering that the daily feed 
intake of mature rats is around 30 gram, the range of daily intake 
of isoflavones in the previous study was approximately equi-
valent to 360~2880 mg/kg of body weight. It is much higher 
levels compared with this study (0.5~30 mg per kilogram of body 
weight), however, no favorable effect on plasma glucose was Jee-Youn Shim et al. 271
found. At this point, it is not clear whether different dosages 
significantly alter glucose tolerance results. On the other hand, 
there have been several studies which have shown that isoflavone 
is favorable toward carbohydrate metabolism. Lee and Lee (2001) 
demonstrated a beneficial effect of soy isoflavone on glycemic 
control in diabetes, by acting as α-glucosidase inhibitors in the 
intestinal brush border uptake of glucose. Also, the benefit of 
soy protein and genistein has been proven in diabetic rats (Lee, 
2006), in which the plasma insulin level was increased and the 
blood glucose level was significantly decreased during the oral 
glucose tolerance test. Dyrskog et al. (2005) demonstrated that 
a soy diet lowered levels of fasting blood glucose and improved 
insulin sensitivity in Type 2 diabetic obese Zucker fatty rats. 
The beneficial effect of soy protein on glucose tolerance and 
insulin sensitivity has been reported also in normal rats (Lavigne 
et al., 2000). From these studies, it appears that soy protein 
including isoflavone may have favorable effect on glucose 
metabolism in either normal or diabetic conditions. The effective 
intake level of soy isoflavones which could exhibit a favorable 
action on glucose metabolism is not suggested from the previous 
reports. In this study, it has been observed that soy isoflavones 
improved glucose tolerance in diabetic rats only at a specific 
dose level (3.0 mg per kilogram of body weight per day). 
Moreover, the diabetic group which showed a hypoglycemic 
response demonstrated a significantly longer GI transit time 
compared with the other diabetic groups. This result suggests 
the possibility of a correlation between GI transit time and 
glucose tolerance in diabetic animals. In other words, the addition 
of soybean isoflavones to the diet may have an effect on the 
control of postprandial blood glucose level by prolonging the 
GI transit time, resulting in slowing the rate of digestion as well 
as absorption of meal components. 
To examine the effect of an isoflavone supplement on liver 
function, the activity of plasma transaminases, GOT and GPT, 
was measured. In the present study, the mean GPT activity levels 
of the ISO-II and ISO-III groups were similar to that of the 
normal group and they were significantly (p<0.05) lower than 
that of the diabetic control and ISO-I groups. The activity of 
GOT was not affected by isoflavone supplement. Ali et al. (2005) 
also observed a significant decrease in AST (=GOT) and ALT 
(=GPT) in rats that were fed isoflavones (0.1% isoflavone 
mixture). Therefore, we can conclude that isoflavones are not 
harmful to the liver at the dosage level up to 30 mg per kilogram 
of body weight because the activity of these enzymes increases 
when the liver is damaged. 
In conclusion, the present study has demonstrated that the 
soybean isoflavone extract may be beneficial to diabetic animals 
by improving their glucose tolerance and suppressing weight loss 
without incurring hepatotoxicity at the daily dosage of 3.0 mg 
per kilogram of body weight. 
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